# TABLE OF CONTENTS

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>TABLE OF CONTENTS</td>
<td>2</td>
</tr>
<tr>
<td>OVERVIEW OF THE GARIODNER FOUNDATION</td>
<td>3</td>
</tr>
<tr>
<td>MISSION, VISION</td>
<td>4</td>
</tr>
<tr>
<td>GOALS</td>
<td>5</td>
</tr>
<tr>
<td>MESSAGE FROM THE CHAIR</td>
<td>6</td>
</tr>
<tr>
<td>MESSAGE FROM THE PRESIDENT/SCIENTIFIC DIRECTOR</td>
<td>7</td>
</tr>
<tr>
<td>2010 YEAR IN REVIEW</td>
<td>8</td>
</tr>
<tr>
<td>REPORT ON 2010 OBJECTIVES</td>
<td>12</td>
</tr>
<tr>
<td>THE YEAR AHEAD: OBJECTIVES FOR 2011</td>
<td>13</td>
</tr>
<tr>
<td>2010 SPONSORS</td>
<td>14</td>
</tr>
<tr>
<td>GOVERNANCE</td>
<td>15</td>
</tr>
<tr>
<td>MEDICAL REVIEW PANEL 2010</td>
<td>18</td>
</tr>
<tr>
<td>MEDICAL ADVISORY BOARD 2010</td>
<td>20</td>
</tr>
<tr>
<td>WIGHTMAN ADVISORY COMMITTEE 2010</td>
<td>22</td>
</tr>
<tr>
<td>GLOBAL HEALTH ADVISORY COMMITTEE 2010</td>
<td>23</td>
</tr>
<tr>
<td>GARIODNER STAFF 2010</td>
<td>24</td>
</tr>
<tr>
<td>COMPENSATION</td>
<td>24</td>
</tr>
<tr>
<td>AUDITORS REPORT</td>
<td>25</td>
</tr>
</tbody>
</table>
The Gairdner Foundation was created in 1957 by James A. Gairdner to recognize and reward the achievements of medical researchers whose work “contributes significantly to improving the quality of human life”. The history of the Foundation is a story of a Canadian organization that has never lost sight of its primary mission – the recognition of scientists it deemed to have made the most important breakthrough discoveries in biomedical science. Its’ recipients were responsible for the discovery of the structure of DNA, the eradication of smallpox, CT scans, MRI machines, the human genome, the cure for ulcers, and the vaccine against HPV to name a few.

Since the first awards were granted in 1959, the Gairdner Awards have become Canada’s foremost international award. They are one of the three most prestigious awards in medical science. Our track record of consistent high quality adjudication and selection by the independent adjudication committees have resulted in global recognition and esteem of the Canada Gairdner Awards.

The Gairdner was incorporated in December 1957 as a charitable corporation under the laws of the Province of Ontario, Canada. Its funds originally derived from the personal gifts of the Founder and members of his family. This inspired and farsighted decision and the faithful stewardship by those who carried on the activities of the Foundation have ensured that the awards continue to inspire the very best health research and have contributed to strengthening Canada’s scientific research capacity and international reputation.
MISSION

• To reward and inspire the highest standards of international excellence by recognizing and rewarding those who have achieved the most important breakthrough discoveries in the field of health research

• To bring to the attention of Canadian scientists and the public, the most important scientific developments globally in the field of health research

• To inspire young Canadian scientists to aspire to the highest levels of scientific excellence and encourage the next generations’ interest in health science research

• To foster the improved communication of ideas among scientists and to facilitate linkages between leading international scientist and Canadian scientists/research institutions

• To enhance Canada’s stature in the global health research community

VISION

• The Canada Gairdner Awards are internationally recognized as pre-eminent awards for the most significant international scientific achievements in health research

• The Canada Gairdner Awards and programs provide inspiration to Canadian researchers, including the next generation, to achieve world-class levels of scientific excellence

• The Canada Gairdner Awards are a source of national pride and contribute to the understanding of the value of medical research to our nation and its future
Our core mandate is to select the annual Canada Gairdner International Awardees. Over the past 50 years, the Foundation has gained a superb international reputation for recognizing and rewarding early the work of the world’s leading scientists.

Biomedical research is fundamentally an international endeavour. The international stature of the awards conveys to the rest of the world that scientific research is both recognized and respected in Canada. The Gairdner Foundation recognizes, encourages and celebrates basic research and in so doing helps to foster a culture of research and innovation.

A unique aspect of the Gairdner Foundation is the National Program, where award recipients contribute a week of their time visiting Universities across Canada. The National Program brings the world’s top scientists to Canada and helps raise the profile of science in our country. This program provides a unique opportunity for Canadian scientists and graduate students to interact with international leaders who represent the best of scientific excellence.

The Foundation plays an important role in scientific life in Canada through its second mission, the annual National Program. This ambitious program makes past and present recipients available to audiences in academic centres across Canada through faculty and graduate student lectures, high school lectures and public forums. It contributes to scientific literacy and increases appreciation of the important role that biomedical research plays in our country.

Our aim is not only to enhance Canada’s stature in the international scientific community, but to facilitate linkages between leading international scientists and Canadian research institutions and to inspire young Canadians to aspire to the highest levels of scientific excellence.
The last year has been an interesting follow up to the 50th Anniversary celebration. We have built on the momentum that was generated by the remarkable events of the 50th anniversary. The federal government support of $20 million enabling us to increase the value of the awards to $100,000 and the change of the name of the Gairdner International Awards to the Canada Gairdner Awards has enhanced recognition for both Canada and the Gairdner Foundation.

This past year has been very busy with the national program in October celebrating the work of the Gairdner Foundation in 21 universities and addressing high school students in most of these sites. Over 3,500 students heard lectures from current and past Gairdner awardees. In addition, major Gairdner symposia have been sponsored in several provinces including the Capturing Innovation for the Public Good Symposium in Toronto and the Vaccine Symposium in Saskatoon. These symposia continue to elevate the profile of the Gairdner Foundation nationally and internationally.

The suggestion by the Board about one year ago that we should partner with Canadian Embassies and Consulates to announce Canada Gairdner International Award winners in their home countries has been a spectacular success. These events truly highlight the impact and importance of the Canada Gairdner International Awards as a tremendous success story for Canada and the Gairdner Foundation. Events will be hosted in the UK, Washington, Israel, Paris, and Japan in 2011.

However, all of this puts considerable stress and increases the work load of the small staff of the Gairdner Foundation Office. The Foundation staff works very hard to raise the funds and to coordinate the multiple activities of the Gairdner Foundation. Over the last year we have welcomed new Board members Kevin Lynch and Cal Stiller. It is critically important to have support from our Board as we work with our donors, both private and public, to ensure a strong future for the Gairdner Foundation. We have created a wonderful success story. Even success stories require ongoing support. We are going to depend on the Board to help our management team if we are to maintain our success into the future.

D. Lorne Tyrrell, OC, AOE, MD/PhD, FRCP, FRSC
Chair,
Gairdner Foundation Board
The Gairdner Foundation’s primary mission, through both its awards and its National Program, is to encourage, reward and celebrate the very best biomedical research in the world through its awards; the Canada Gairdner International Awards, the Canada Gairdner Global Health Award, and the Canada Gairdner Wightman Award.

The Foundation plays an important role in scientific life in Canada through its mission of raising the profile of science through the annual National Program. This ambitious program makes past and present recipients available to audiences in academic centres across Canada through faculty and graduate student lectures, high school lectures and public forums. It contributes to scientific literacy and increases appreciation of the important role that biomedical research plays in our country.

The Gairdner Foundation is a partnering organization and we are grateful to the volunteer scientists and universities across Canada for their ongoing and enthusiastic participation in our programs. We are particularly indebted to the scientists from Canada and abroad who serve on our four adjudication committees. Their dedication to selecting awardees solely on the basis of excellence is the very cornerstone of our reputation as one of the world’s leading awards.

Finally, we thank our 2010 sponsors, without whom the National Program and the Student Outreach Program would not have been possible.

John Dirks, CM, MD
President & Scientific Director
The Gairdner Foundation
There were 7 outstanding recipients of the Canada Gairdner International Awards, the Canada Gairdner Wightman Award and the Canada Gairdner Global Health Award in 2010.

2010 Canada Gairdner Award Recipients

William G. Kaelin Jr., M.D., Dana-Farber Cancer Center and Howard Hughes Medical Institute, Boston, MA
for identification of molecular mechanisms of oxygen sensing in the cell fundamental for many physiological processes and important for normal homeostasis and disease

Peter J. Ratcliffe M.D., University of Oxford, Oxford
for identification of molecular mechanisms of oxygen sensing in the cell fundamental for many physiological processes and important for normal homeostasis and disease

Gregg L. Semenza M.D., Ph.D., The Johns Hopkins Institute for Cell Engineering, Baltimore, MD
for identification of molecular mechanisms of oxygen sensing in the cell fundamental for many physiological processes and important for normal homeostasis and disease

William A. Catterall Ph.D., Department of Pharmacology, University of Washington Seattle, WA
for discovery of the voltage-gated sodium channel and calcium channel proteins and the elucidation of their function and regulation

Pierre Chambon M.D., Institut de Génétique et de Biologie Moléculaire et Cellulaire, France
for contributions to the elucidation of fundamental mechanisms of transcription in animal cells and for contributions to the discovery of the nuclear receptor superfamily paving the way to a molecular understanding of many fundamental biological processes

Nick White, M.D. D.Sc., Canada Gairdner Global Health Award recipient
Mahidol Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Bangkok
for his definitive clinical studies on the effectiveness of artemesinins in the treatment of malaria and for elucidating the basis for the use of artemisinin combination treatments (ACT) to prevent resistance

Cal Stiller C.M., O.Ont., M.D., Professor Emeritus, Canada Wightman Award recipient
University of Western Ontario and Chair, Ontario Institute for Cancer Research
for his pioneering work in transplantation and diabetes, and as a remarkable entrepreneur and builder of private and public institutions that have greatly enriched the research landscape of Canada.
Special Symposia

During its 51st year, Gairdner initiated a new series of special symposia to take place at various universities across Canada outside of the traditional October Gairdner week.

**Toronto Capturing Innovation for the Public Good (September 15)**

To bring together representatives of government, academia and business to look at the issue of translating research into effective technologies and services.

Featured speakers included Dr. Cal Still (2010 Canada Gairdner Wightman Award), Dr. Leroy Hood (President, Institute for Systems Biology), Dr. Robert Langer (MIT), Dr. Lon Cardon (GlaxoSmithKline), Dr. Stephen Friend (Sage Bionetworks), Mr. Robert Klein (California Institute of Regenerative Medicine), Dr. Michael Hayden (University of British Columbia), Tom Hudson (Ontario Institute for Cancer Research), and the Hon. Kevin Lynch (Bank of Montreal).

**Saskatoon Vaccine Symposium at VIDo (October 21-22)**

This vaccine symposium focused on animal human interface.

Speakers included Dr. Frederick Murphy (University of Texas), Dr. Lorne Babiuk (University of Alberta), Dr. Willem Hanekom (University of Cape Town), Dr. Greg Poland (Mayo Clinic), Dr. David Butler-Jones (PHAC), Dr. Albert Osterhaus (University of Rotterdam), Dr. Farshad Guirakhoo (France), Dr. Michael Houghton (University of Alberta), Dr. Don McManus (Queensland Institute of Medical Research) and Dr. Neil Cashman (University of British Columbia).

National Program

The annual National Program took place at 21 universities this year, including nine in Ontario, four in Quebec, three in the Maritimes, and five in the West. All faculty lectures were well attended, continuing to attract large audiences.

The program began in Atlantic Canada, where Dr. David Sackett (Emeritus Professor, McMaster University), recipient of the 2009 Canada Gairdner Wightman Award spoke at Memorial University (Oct 12), Dalhousie (Oct 13) and University of Prince Edward Island (Oct 15).
Other Gairdner week lectures included the following:

- Université de Montréal: Dr. Pierre Chambon, University of Strasbourg, 2010 Canada Gairdner Laureate
- McGill University: Dr. Pierre Chambon, 2010 Canada Gairdner Laureate and Dr. Nahum Sonenberg (McGill University), 2008 Canada Gairdner Laureate
- Université Laval: Dr. Pierre Chambon, 2010 Canada Gairdner Laureate
- Université de Sherbrooke: Dr. David Sackett (McMaster University), 2009 Canada Gairdner Laureate
- University of Waterloo, University of Western Ontario and McMaster University: Dr. Peter Ratcliffe (University of Oxford), 2010 Canada Gairdner International Laureate
- University of Ottawa and University of Guelph: Dr. Greg Semenza (John Hopkins University), 2010 Canada Gairdner Laureate
- Carleton University: Dr. Nicholas White (Oxford and Mahidol Universities), 2010 Canada Gairdner Global Health Laureate
- York University: Dr. Phillip Marsden (University of Toronto), Co-chair Gairdner Medical Review Panel, and Dr. Gregg Semenza
- Lakehead University: Dr. Ravi Menon (University of Western Ontario), member the Gairdner Medical Review Panel. (event delayed until February 16, 2011 due to labour issues at the university)
- Queen's University: Dr. Pierre Chambon, 2010 Canada Gairdner Laureate
- University of Manitoba: Dr. William Kaclin Jr. (Harvard University), 2010 Canada Gairdner Laureate
- University of Saskatchewan: Dr. Cal Stiller (University of Western Ontario), 2010 Canada Gairdner Wightman Laureate
- University of Calgary: Dr. William Kaclin and Professor Kim Nasmyth (Oxford University), 2007 Gairdner Laureate and Dr. Cal Stiller
- University of Alberta: Dr. William Catterall (University of Washington), 2010 Gairdner Laureates Dr. Nicholas White, and Dr. Cal Stiller
- University of British Columbia: Dr. William Catterall and Dr. Nicholas White

**Student Outreach Program**

The Student Outreach Program in 2010 included 17 schools: York, Toronto, Carleton, Lakehead, Montréal, McGill, Queen’s, Waterloo, Western, University of Prince Edward Island, Memorial, Dalhousie, Manitoba, Saskatchewan, Alberta, Calgary and UBC.

In total 125 high schools participated, and a total of 3,535 students, our largest audience ever for these programs.

Many recipients express real pleasure at being given the opportunity to speak to a younger audience. For some of them, it is the first time they have spoken to such a young but invariably enthusiastic group. One of the highlights was the 600 students who turned out in Montreal at College Jean Brébeuf to hear 2010 recipient Pierre Chambon speak.
The 2010 events culminated in Toronto with three days of lectures and symposia, October 27-29.

- **Eradicating Malaria: Prospects and Perils**
  Full day symposium held at MaRS included lectures by Dr. Nicholas White (2010 Canada Gairdner Global Health Award), Dr. Ripley Ballou (GlaxoSmithKline), Dr. Feiko ter Kuile (Liverpool School of Tropical Medicine), Dr. David Brandling-Bennett (Bill & Melinda Gates Foundation), Dr. Larry Slutsker (US Centers for Disease Control and Prevention), Dr. Dean Jamison (University of Washington)

- **Minds That Matter 2010 Canada Gairdner recipients lectures**
  The seven award recipients each spoke about their work and the day concluded with a lecture by 2010 Nobel Prize Laureate, Dr. Jack Szostak (Harvard Medical School)

- **Epigenetics and Genome Function Symposium**
  One day symposium included state of the art lectures by 2007 Gairdner Award Laureate Dr. David Allis (The Rockefeller University), Dr. Adrian Bird (University of Edinburgh), Dr. Michael Meany (McGill University), Dr. Shiv Grewal (National Cancer Institute), Dr. Andrew Feinberg (Johns Hopkins University), Dr. Art Petronis (Centre for Addiction and Mental Health)

There were a number of additional programs added on at the request of several organizations.

Dr. Cal Stiller spoke and then participated in a panel discussion on *Challenges to and Strategies for Biotech Innovation* on Monday, October 25, 2010 at the University of Calgary.

Dr. Nicholas White delivered the Plenary Address at the Canadian Conference on Global Health organized by the Canadian International Health Society on Sunday October 31 in Ottawa. He also spoke at the Health Canada Science Forum on Tuesday, November 2.
1. Maintain the Highest Standards Selecting Recipients of the Awards

Additions to the Medical Advisory Board in 2010 include:

- **Dr. Suzanne Cory**, Ph.D., Molecular Genetics of Cancer Division, Walter and Eliza Hall Institute of Medical Research, and one of Australia’s most distinguished molecular biologists

- **Dr. Guy Rouleau**, M.D., Ph.D., Department of Medicine, Université de Montréal, and Director, Research Centre, Saint-Justine Hospital, has contributed to the identification of over 10 gene-causing diseases

- **Dr. Robert Roberts**, M.D., President and Chief Executive Officer, University of Ottawa Heart Institute, is considered one of the founders of molecular cardiology

2. Inspire Canadian Scientists to Seek Excellence

- We continue to profile Canada as a place where science is recognized and respected through the internationally acclaimed Canada Gairdner Awards, and its’ National Program

- Annual awards dinner, held at the Royal Ontario Museum attended by 530 leaders of government, academe, business and pharma. Honoured guest was His Excellency, The Right Honourable David Johnston, Governor General of Canada

- Two special events on innovation held in Toronto and Calgary, involving researchers, government leaders and successful biotech entrepreneurs who spoke about research and innovation and why it is important to Canada

3. Foster Collaboration between Canadian and International Scientists

- Gairdner continues to bring scientists from abroad to meet with researchers in Canada through lectures, small group discussions, grand rounds, and social interactions

- Special symposia, distinct from the usual National Program were held in Toronto and Saskatoon

- 3 International schools, Harvard University, University of Washington and Oxford University purchased tables at the awards dinner, the first time for each institution

- An estimated 8,000 people attended Gairdner lectures and symposia in 2010, including senior scientists, postgraduate and graduate students, medical students, and the public

- Held reception at Canadian High Commission in London for Peter Ratcliffe and Nicholas White

4. Enhance and encourage a culture of science in Canada

- The student Outreach Program expanded to 17 universities with the participation of 125 high school and 3,535 students across Canada. At Lakehead, where 150 students attended, a large group travelled 4 hours by bus to do so

- The National Program took place at 21 Universities across Canada

- Selected events were webcast, including the Toronto talks made available on the University of Toronto website, the Gairdner website and ITunes (through the MaRS portal)

- Edelman's media coverage resulted in a multitude of newspaper and internet stories. Statistics from Edelman indicate we achieved over 22 million media ‘hits’ during Gairdner week
THE YEAR AHEAD: OBJECTIVES FOR 2011

The Foundation remains committed to excellence and foresight which has resulted in our reputation as a leading international prize. In the past decade, science and technology in general, and the life sciences in particular, have been identified as a critical basis for competitive success in the global economy. The Gairdner Foundation continues its initiatives to bring the science agenda to the forefront.

1. **Maintain the Highest Standards Selecting Recipients of the International, Wightman and Global Health Awards**

   - Five leading Canadian researchers will join the Medical Review Panel:
     Robert Hegele M.D., University of Western Ontario; Heidi McBride Ph.D., University of Ottawa Heart Institute; Pam Ohashi Ph.D., University of Toronto; Morag Park Ph.D., McGill University and Richard Wozniak Ph.D., University of Alberta
     - Dr. Roger Glass M.D. Ph.D., Director Fogarty Institute, Washington DC and Dr. Zulfiqar Bhutta Ph.D., Professor, Aga Khan University, Karachi, Pakistan will join the Canada Gairdner Global Health Advisory Committee
     - Dr. Catherine Whiteside M.D. Ph.D., Dean of Medicine, University of Toronto has been added to the selection committee for the Canada Gairdner Wightman Award

2. **Inspire Canadian Scientists to Seek Excellence by raising the profile of the awards**

   - Through the Canada Gairdner International Awards, profile Canada in the media and in academic centres throughout the world, as a place where the importance of science is recognized
   - Continue to build the public profile of the Gairdner Foundation through advertising and media coverage:
     - Maintain Globe & Mail as our national media sponsor
     - Videotape major talks for website distribution
     - Increase international exposure through April announcement ads in Science and Nature. Encourage media coverage abroad through press releases and background packages on Announcement Day
     - Continue relationship developed with The Lancet to cover spring announcement of the 2012 recipients
     - Encourage coverage of 2011 recipients at their own academic institutions in Canada and abroad
     - Complete a rebranding and communications strategy
     - Hold receptions at Canadian Embassies in the home country of all 2011 recipients

3. **Enhance and encourage a culture of science in Canada**

   - Maintain National Program of University Lectures at 21 institutions across Canada
   - Maintain Student Outreach Program in at least 16 academic institutions across Canada
   - Increase media coverage of scientists and the importance of their research
   - A special symposium will take place in Montreal in May 2011 on Mental Health issues
THE GAIRDNER FOUNDATION VALUES THEIR 2010 SPONSORS

GOVERNMENT SUPPORT

Canada  Ontario  Government of Alberta

NATIONAL PARTNER

CIHR  IRSC

GOLD CIRCLE

imagination at work  Don Rix Family Foundation

SILVER CIRCLE

MERCK FROSST  BURROUGHS WELLCOME FUND  AMGEN

BRONZE CIRCLE

University Health Network  RBC Foundation  LONDON DRUGS  Bill & Melinda Gates Foundation

SUPPORTERS

Roche  Lilly  Pfizer  wellcome trust

MEDIA SPONSOR

THE GLOBE AND MAIL

Global Health Research Initiative  Initiative de Recherche en Santé Mondiale
The Gairdner Foundation is governed by a 16 member Board of Directors, including 2 ex-officio members. The Board is comprised of individuals who bring their expertise from the academic, private and public sectors. Board members are nominated and appointed for an annual term. Directors are not compensated for their regular Board and Committee duties.

The Board is responsible for overseeing the management of the organization, and through its committees, conducts detailed examinations of issues and opportunities. The Directors provide strategic insight and leadership, as well as effective governance for the Foundation and work diligently to maintain and extend the capacity of the Foundation to achieve its purpose and goal.

The Board meets a minimum of twice each year. Directors of the Board take their role seriously and to the best of their ability, strive to be active participants in all Board and Committee meetings. During 2010, the Board met 3 times, with attendance or participation by conference call averaging in excess of 80%.

**BOARD OF DIRECTORS 2010**

Dr. D. Lorne Tyrrell  
Board Chair  
Edmonton

Gary Goldberg  
President, Gadango Inc.  
Toronto

Jacques Menard  
Chairman, BMO Nesbitt Burns and  
President, BMO Financial Group,  
Montreal

Lynne Upton  
Vice-Chair  
Victoria

Edward Kisling  
President, Victoria Management  
Strategies Inc., Victoria

Eric Newell  
Chancellor Emeritus, University  
of Alberta  
Edmonton

Dr. John Dirks  
President/Scientific Director  
Toronto

Brandt C. Louie  
Chairman and CEO, H.Y. Louie Co.  
Limited  
Chairman of the Board, London  
Drugs Limited  
Vancouver

Joseph Rotman  
Chairman and CEO, Roy-L Capital  
Corporation, Toronto

Jacques Bougie  
Corporate Director  
Montreal

The Honourable Kevin Lynch,  
PC  
Vice-Chair, BMO Financial Group,  
Toronto

Melissa Todd  
Waterloo

Bren Gairdner  
Secretary-Treasurer  
Alberta

Ann McCaig  
Chancellor Emeritus, University  
of Calgary
COMMITTEES

The Board has in place a number of standing committees which help the Board discharge its duties.

Executive and Compensation Committee
D. Lorne Tyrrell, Chair
Joseph Rotman
Lynne Upton
Kevin Lynch

Audit Committee- meet 3-4 times per year
Jacques Bougie, Chair
Bren Gairdner
Gary Goldberg
Eric Newell

Investment Committee- meet 4 times per year
Brandt Louie, Chair
Edward Kisling
Eric Newell
Jacques Menard

Governance and Nominating Committee- meet minimum of 1 time per year
D. Lorne Tyrrell, Chair
Joseph Rotman
Lynne Upton
Ann McCaig

Financial Highlights
The Gairdner Foundation maintains proper financial controls and sound management practices to ensure the best use of its public and private funds. Our external auditors issued an unqualified audit opinion about the Gairdner Foundation financial statements which appear at the end of this report.

In 2008, a funding agreement was executed between CIHR and the Gairdner Foundation outlining the terms of a $20 Million grant received from Canadian Institutes of Health Research. Proceeds from the grant were used to establish an endowment to support and enhance the Awards, and to ensure that the Canada Gairdner Awards continue to grow in stature on the international stage.

In 2008, the Foundation also received $2 million from the Alberta government for the purpose of expanding the Gairdner Outreach Program in Alberta.

These funds have been invested together with the original family endowment under the guidance of the Investment Committee, and in accordance with the terms of these agreements and prudent governance. The investment policy adopted by the Board has been designed with the principal objective being preservation of capital over the long-term.
Planning and Monitoring Investments

The Foundation has a duty to ensure responsible stewardship of funds. The Investment Committee oversees the management and investment of the Gairdner Foundation funds in compliance with our funding agreements. The Foundation’s funds have been invested with 3 major objectives:

- Preservation of capital
- Income to meet the administrative costs and award objectives of the Foundation
- Growth in the ‘capital’ value of the Portfolio’s assets in real (inflation-adjusted) terms

In reviewing the Foundation’s investment objectives, risk tolerance, income requirements and liquidity needs, a long term target asset allocation of 50% fixed income and 50% equity was approved by the Board in 2008. As of December 31, 2010, the long term asset allocation has been achieved.

The investment strategy and policy are reviewed annually and the portfolio is reviewed on a quarterly basis. No issues were identified in the 2010 reviews.

The market value of the investment portfolio increased to $27.2 million from $26 million at the end of 2009. Overall, the portfolio yielded a return on investment of 6.1% in fiscal 2010 vs. the benchmark of 8.4%. This underperformance can be attributed to portfolio composition and diversification. In 2010, the Canadian TSX was up 18% driven largely by the energy and materials sectors, however our portfolio is more broadly diversified.

Results of Operations

Income for the year totaled $2.8 million, made up of $1.2 million from contributions and sponsorship from non-governmental sources and table sales (42%), $1.4 million from government (50%), and $0.23 million from investment income (8%). This split remains basically unchanged from 2009. Every year the Foundation seeks sponsors from both the public and private sector.

In absolute dollars, income from government and the private sector were down from 2009, as special 50th Anniversary events were not repeated in 2010. Government and Private sector support was reduced by $0.5 million. After the very significant market recovery in 2009, income from investments decreased slightly in 2010, however performance was in line with expectations.

Expenses were $2.2 million for the year, down by $0.1 million from 2009. This decrease related to the slightly reduced National Program after the special 50th anniversary year. Two new special forums were added in 2010, however these programs were not as costly as the 50th anniversary special symposia.
<table>
<thead>
<tr>
<th>Name</th>
<th>Position and Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jack Gauldie, Co-Chair</td>
<td>Department Of Pathology &amp; Molecular Medicine, Director, Center for Gene Therapeutics, McMaster University</td>
</tr>
<tr>
<td>Philip Marsden, Co-Chair</td>
<td>Keenan Chair in Medical Research Department of Medicine, Renal Division, University of Toronto</td>
</tr>
<tr>
<td>Samuel Aparicio</td>
<td>Nan &amp; Lorraine Robertson Chair, UBC/BC Cancer Agency</td>
</tr>
<tr>
<td>Stephen Archer</td>
<td>Chief, Section of Cardiology Department of Medicine, University of Chicago</td>
</tr>
<tr>
<td>Cheryl Arrowsmith</td>
<td>Ontario Cancer Institute, Department of Medical Biophysics &amp; Banting &amp; Best Department of Research, University of Toronto</td>
</tr>
<tr>
<td>Samuel Benchimol</td>
<td>Department of Biology, Canada Research Chair in Biomedical Health, York University</td>
</tr>
<tr>
<td>Mickie Bhatia</td>
<td>Stem Cell and Cancer Research Institute Michael G. DeGroote School of Medicine, McMaster University</td>
</tr>
<tr>
<td>Eric Brown</td>
<td>Canada Research Chair in Chemical Biology, Department of Biochemistry &amp; Biomedical Science, McMaster University</td>
</tr>
<tr>
<td>Benoit Chabot</td>
<td>Canada Research Chair in Functional Genomics, Université de Sherbrooke</td>
</tr>
<tr>
<td>Stephen Collins</td>
<td>Associate Dean, Research Faculty of Health Sciences, McMaster University</td>
</tr>
<tr>
<td>Jacques Corbeil</td>
<td>Director, Quebec Centre for Genomics, Canada Research Chair in Medical Genomics, Université Laval</td>
</tr>
<tr>
<td>James Cross</td>
<td>Director, Institute of Maternal and Child Health, Faculty of Medicine, University of Calgary</td>
</tr>
<tr>
<td>Jacques Drouin</td>
<td>Chair in Molecular Genetics, Institute de Reserches Cliniques de Montreal</td>
</tr>
<tr>
<td>Volker Gerdts</td>
<td>Associate Director (Research), Vaccine and Infectious Disease, University of Saskatchewan</td>
</tr>
<tr>
<td>Ronald Gill</td>
<td>Professor of Surgery and Scientific Director, Colorado Center for Transplantation Care, University of Colorado</td>
</tr>
<tr>
<td>Mark Glover</td>
<td>Professor of Biochemistry, University of Alberta</td>
</tr>
<tr>
<td>Robert Hegele</td>
<td>Jacob J. Wolfe Distinguished Medical Research Chair, Canada Research Chair in Human Genetics, University of Western Ontario</td>
</tr>
<tr>
<td>Philip Hieter</td>
<td>Director, Michael Smith Laboratories, University of British Columbia</td>
</tr>
<tr>
<td>Jack Jhamandas</td>
<td>Associate Dean Research Chair in Alzheimer Research, Faculty of Medicine &amp; Dentistry, University of Alberta</td>
</tr>
<tr>
<td>Jean-Pierre Julien</td>
<td>Canada Research Chair in Mechanisms of Neurodegeneration, Université de Laval</td>
</tr>
<tr>
<td>David Lillicrap</td>
<td>Department of Pathology &amp; Molecular Medicine, Queen’s University</td>
</tr>
<tr>
<td>Jonathan Lytton</td>
<td>University of Calgary, Health Research Innovation Center</td>
</tr>
<tr>
<td>J. (Quim) Madrenas</td>
<td>Canada Research Chair in Immunobiology, University of Western Ontario, Head of Immunology, Robarts Research Institute</td>
</tr>
<tr>
<td>Jean Marshall</td>
<td>Head of Microbiology &amp; Immunology Dalhousie University</td>
</tr>
</tbody>
</table>
Heidi McBride  
Department of Pathology and Laboratory Medicine, University of Ottawa Heart Institute

Ravi Menon  
Canada Research Chair in Functional & Molecular Imaging, Deputy Scientific Director, Robarts Research Institute, University of Western Ontario

Ralph Meyer  
Director, National Cancer Institute of Canada, Departments of Oncology & Medicine, Queen's University

Pamela Ohashi  
Senior Scientist, Ontario Cancer Institute, Princess Margaret Hospital

Morag Park  
Director Molecular Oncology Group, Rosalind & Morris Goodman Cancer Centre, McGill University

Steve Scherer  
Director, Center for Applied Genomics, Hospital for Sick Children and Director, McLaughlin Centre for Molecular Medicine, University of Toronto

Rafik-Pierre Sékaly  
Canada Research Chair in Cellular Biology & Biological Imaging for the Study of Infection & Human Immunodeficiency Virus, Université de Montréal

Holger Shunemann  
Chair, Michael Gent Professor in Healthcare Research, Department of Clinical Epidemiology & Biostatistics, McMaster University

David Williams  
Department of Biochemistry, University of Toronto

Richard Wozniak  
Professor, Department of Cell Biology, University of Alberta

Jeff Wrana  
Senior Investigator, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Department of Medical Genetics, University of Toronto
<table>
<thead>
<tr>
<th>Name</th>
<th>Title</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>John Dirks</td>
<td>President and Scientific Director, The Gairdner Foundation</td>
<td></td>
</tr>
<tr>
<td>Jack Gauldie, Co-Chair, MRP</td>
<td>Department of Pathology &amp; Molecular Medicine, Director, Center for Gene Therapeutics, McMaster University</td>
<td></td>
</tr>
<tr>
<td>Philip Marsden, Co-Chair, MRP</td>
<td>Keenan Chair in Medical Research Department of Medicine, Renal Division, University of Toronto</td>
<td></td>
</tr>
<tr>
<td>Alain Beaudet</td>
<td>President, Canadian Institutes of Health Research, Ottawa</td>
<td></td>
</tr>
<tr>
<td>Professor Sir John Bell</td>
<td>Regius Professor of Medicine, University of Oxford, Oxford, England</td>
<td></td>
</tr>
<tr>
<td>Elizabeth Blackburn</td>
<td>Professor in Biology &amp; Physiology University of California, San Francisco</td>
<td></td>
</tr>
<tr>
<td>Sydney Brenner</td>
<td>Distinguished Professor, The Salk Institute, San Diego</td>
<td></td>
</tr>
<tr>
<td>Linda Buck</td>
<td>Howard Hughes Medical Institute Director of Basic Science, Fred Hutchinson Cancer Research Center, Professor of Physiology and Biophysics, University of Washington</td>
<td></td>
</tr>
<tr>
<td>John Challis</td>
<td>President &amp; CEO, Michael Smith Foundation</td>
<td></td>
</tr>
<tr>
<td>David Colman</td>
<td>Director, Montreal Neurological Institute, Wilder Penfield Professor of Neuroscience, McGill University</td>
<td></td>
</tr>
<tr>
<td>Suzanne Cory</td>
<td>Molecular Genetics of Cancer Division, Walter and Eliza Hall Institute of Medical Research Australia</td>
<td></td>
</tr>
<tr>
<td>Victor Dzau</td>
<td>James B. Duke Professor of Medicine, Chancellor, Duke University</td>
<td></td>
</tr>
<tr>
<td>Jeffrey Flier</td>
<td>Dean of Faculty of Medicine, Harvard Medical School</td>
<td></td>
</tr>
<tr>
<td>Cyril Frank</td>
<td>Professor and Chief, Division of Orthopaedic Surgery, Director, Alberta Bone &amp; Joint Health Institute, University of Calgary</td>
<td></td>
</tr>
<tr>
<td>F. Ulrich Hartl</td>
<td>Director Max-Planck-Institut of Biochemie, Martinsried, Germany</td>
<td></td>
</tr>
<tr>
<td>Michael Hayden</td>
<td>Canada Research Chair in Human Genetics &amp; Molecular Medicine, University of British Columbia</td>
<td></td>
</tr>
<tr>
<td>Robert Horvitz</td>
<td>Investigator, Howard Hughes Medical Institute, Neurobiologist and Geneticist, Massachusetts General Hospital</td>
<td></td>
</tr>
<tr>
<td>Roderick McInnes</td>
<td>Director of Research, Jewish General Hospital, Lady Davis Research Institute, Montreal</td>
<td></td>
</tr>
<tr>
<td>Ben Neel</td>
<td>Director, Ontario Cancer Institute, Professor of Medical Biophysics, University of Toronto</td>
<td></td>
</tr>
<tr>
<td>Ronald Pearlman</td>
<td>Professor, Department of Biology, Director, Core Molecular Biology Facility, York University</td>
<td></td>
</tr>
<tr>
<td>Richard Rachubinski</td>
<td>Chair, Department of Cell Biology, University of Alberta</td>
<td></td>
</tr>
<tr>
<td>Robert Roberts</td>
<td>President &amp; CEO, University of Ottawa Heart Institute</td>
<td></td>
</tr>
<tr>
<td>Guy Rouleau</td>
<td>Canada Research Chair in Genetics of the Nervous System, Professor, Department of Medicine, Université de Montréal</td>
<td></td>
</tr>
<tr>
<td>Phillip Sharp</td>
<td>Institute Professor, David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology</td>
<td></td>
</tr>
</tbody>
</table>
Professor J.G. Patrick Sissons
Regius Professor, Physic,
University of Cambridge School of Clinical Medicine, University of Cambridge, Director, Cambridge University Health Partners

Ralph Steinman
Henry G. Kunkel Professor and Senior Physician, The Rockefeller University

Lap-Chee Tsui
Vice Chancellor, University of Hong Kong

Michael Tyers
Investigator, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Professor, Department of Medical Genetics & Microbiology, University of Toronto School of Biological Sciences, University of Edinburgh
<table>
<thead>
<tr>
<th>Name</th>
<th>Title</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>John Dirks, Chair</td>
<td>President and Scientific Director</td>
<td>The Gairdner Foundation</td>
</tr>
<tr>
<td>Richard Murphy</td>
<td></td>
<td>Richard Murphy &amp; Associates</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Boston</td>
</tr>
<tr>
<td>Professor Sir John Bell, FRS, PMedSci</td>
<td>Regius Professor of Medicine</td>
<td>University of Oxford</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>John Challis, Ph.D., FRSC</td>
<td>President &amp; CEO</td>
<td>Michael Smith Foundation</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sir Keith Peters, M.D., FRS</td>
<td>Emeritus Regius Professor of Physic</td>
<td>University of Cambridge, UK</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Victor Dzau, M.A., M.D.</td>
<td>James B. Duke Professor of Medicine</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Chancellor, Duke University</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Janet Rossant, Ph.D., FRS, FRSC</td>
<td>Chief of Research &amp; Senior Scientist</td>
<td>Research Institute, Hospital for Sick Children</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Toronto</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Henry Friesen, M.D., FRSC</td>
<td>Distinguished Professor Emeritus</td>
<td>University of Manitoba</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jean Rouleau, M.D., FRCPC</td>
<td>Dean Faculty of Medicine</td>
<td>Université de Montréal</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jack Gauldie, Ph.D., FRSC</td>
<td>Department Of Pathology &amp; Molecular Medicine</td>
<td>McMaster University</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Joseph Martin, M.D., Ph.D.</td>
<td>Edward R. &amp; Anne G. Leffler Professor of Neurobiology</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Dean Emeritus, Harvard Medical School</td>
<td></td>
</tr>
</tbody>
</table>
GLOBAL HEALTH ADVISORY COMMITTEE

John Dirks (Co-Chair)  
President and Scientific Director, Gairdner Foundation

Salim Abdool Karim, MD  
Pro Vice-Chancellor (Research), University of KwaZulu-Natal

Professor Sir John Bell, FRS, PMedSci, (Co-Chair)  
Regius Professor of Medicine, University of Oxford

Jeffrey Koplan, MD, MPH  
Vice President for Global Health, Emory Global Health Institute, Emory University

Alan Bernstein, OC, Ph.D., FRSC  
Executive Director, Global HIV Vaccine Enterprise

Allan Ronald, MD  
Professor Emeritus, Medical Microbiology, University of Manitoba

Haile Debas, MD  
Executive Director, UCSF Global Health Sciences

Peter Tugwell, MD, MSc, FRCPC  
Director, Centre for Global Health, IPH/IRSP, University of Ottawa

Professor Brian Greenwood, CBE, FRS  
Professor of Tropical Medicine, London School of Hygiene & Tropical Medicine

Tachi Yamada, MD  
President, Global Health Program, Bill and Melinda Gates Foundation

Prabhat Jha, MD, Ph.D.  
Director, Centre for Global Health Research, University of Toronto

Kiyoshi Kurokawa, MD  
Professor, National Graduate Institute for Policy Studies, Tokyo
Dr. John Dirks  
President and Scientific Director

Sheila Robinson  
Vice President External Relations

Penny Balberman  
Finance Director

Nora Cox  
Office Manager

Misha Shaal  
Administrative Assistant

**COMPENSATION**

**DIRECTORS**
Directors are not compensated for regular Board and Committee duties. They may, however, be compensated for any reasonable out-of-pocket expenses incurred while performing their duties or attending Foundation meetings.

**SENIOR OFFICERS**
For the fiscal year ending December 31, 2010, compensation for senior officers was within the following annual salary range:

**Dr. John Dirks**  
President and Scientific Director  
$206,000-250,000